By Fineline Cube 
China-based Kangpu Biopharmaceuticals, Ltd announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase IIb study assessing its KPG-818 in patients with moderate to severe cutaneous manifestations of systemic lupus erythematosus (SLE). This approval marks a significant step forward in the clinical development of KPG-818 for addressing unmet medical needs in SLE patients.
KPG-818 Mechanism and Clinical Performance
KPG-818 is a novel oral molecular glue modulator of the E3 ubiquitin ligase complex CRL4-CRBN. It has demonstrated high binding affinity to CRBN and potent degradation of zinc-finger transcription factors Aiolos (IKZF3) and Ikaros (IKZF1). In the Phase IIa clinical study in SLE patients completed in the US, KPG-818 was well tolerated and showed promising preliminary efficacy in patients with cutaneous manifestations of SLE. Additionally, KPG-818 was well tolerated in healthy subjects in a Phase I clinical study completed in China.-Fineline Info & Tech